| Original language | English |
|---|---|
| Pages (from-to) | 2762-2766 |
| Number of pages | 5 |
| Journal | Addiction |
| Volume | 117 |
| Issue number | 11 |
| DOIs | |
| Publication status | Published - Nov 2022 |
| Externally published | Yes |
Bibliographical note
Funding Information:L.C. is employed by the University of British Columbia, where he is the Director of the Centre for Gambling Research at UBC. The Centre is funded by the Province of British Columbia government and the British Columbia Lottery Corporation (BCLC), a Canadian Crown Corporation. He holds further research funding from the Natural Sciences and Engineering Research Council of Canada and the British Columbia Ministry of Finance. He has received speaker travel reimbursements from the National Association of Gambling Studies (Australia), the National Center for Responsible Gaming (United States) and Alberta Gambling Research Institute (Canada) and reviewer honoraria from the National Center for Responsible Gaming (United States) and Gambling Research Exchange Ontario (Canada). He has not received any further direct or indirect payments from the gambling industry or groups substantially funded by gambling. He has received royalties from Cambridge Cognition Ltd from the licensing of a neurocognitive test.
Funding Information:
J.H. has no institutional or other associations which he believes cause a conflict of interest. He has not received any funds (direct or indirect) from the alcohol, tobacco or gambling industries, although he has received funding related to commissioned research from Systembolaget, the Swedish government‐owned alcohol retail monopoly and Alko, its Finnish equivalent. His research is funded by grants, commissions and consultancy projects from research councils, medical charities and UK or international government bodies. He has also received monies to cover travel and subsistence expenses relating to speaking engagements from public and charitable bodies. He has received personal payments from the Western Australian Government (for a report on alcohol pricing policy) and from other public and charitable bodies for peer review activities.
Funding Information:
In the past 5 years, W.H. has not received fees or funding of any kind from alcohol, pharmaceutical or tobacco companies. His research funding has been from the Australia Research Council and the National Health and Medical Research Council of Australia. He received fees for preparing a literature review of the adverse health effects of cannabis from WHO (2016) and fees for reviewing evidence on the medical benefits of cannabis from: the Therapeutic Goods Administration of Australia (2017–2018); the EMCDDA (2018); and the International Narcotics Control Board (2018).
Funding Information:
In the past 3 years, J.M. declares research grants from the National Institute for Health Research (NIHR; randomized controlled trial of depot naltrexone for OUD, and a randomized controlled trial of acamprosate for alcohol use disorder); and the NIHR Biomedical Research Centre for Mental Health at South London and Maudsley NHS Mental Health Foundation Trust (SLaM; randomized controlled trial of novel cognitive therapy for cocaine use disorder). He has part‐time employment as Senior Academic Adviser for the Alcohol, Drugs, Tobacco and Justice Division, Health and Wellbeing Directorate, Public Health England and is a clinical academic consultant for the US National Institute on Drug Abuse, Centre for Clinical Trials Network. J.M. declares an unrestricted research grant at IoPPN and SLaM from Indivior via Action on Addiction for the present study and unrestricted research grant funding at IoPPN and SLaM from Indivior for a 3‐year, multi‐centre, randomized controlled trial of injectable depot buprenorphine (from 2019). He has received honoraria and travel support from PCM Scientific and Martindale for the Improving Outcomes in Treatment of Opioid Dependence conference (2018). He holds no stocks in any company.
Funding Information:
M.H. holds a full‐time post at Population Health Sciences, Bristol Medical School, University of Bristol. M.H. has never received any funding from alcohol or tobacco companies but has received unrestricted research grants as co‐investigator and speaker fees from pharmaceutical companies and has received funds from charities with an interest in . M.H. has no connection to any patents, copyrights or businesses relating to the addiction field. M.H. is Principle Investigator on multiple research grants held at University of Bristol which are in the field of addiction. Addiction
Funding Information:
J.C. holds a full‐time appointment at the University of Amsterdam, Department of Psychology. Her research has been supported by grants from the US National Institute of Health (NIH‐NIDA); National Science Foundation, Netherlands (NWO); the Netherlands Organization for Health Research and Development (ZON‐MW); and intramural funding from different Dutch universities. She has no financial conflicts of interest to declare.
Funding Information:
J.B. works at University College London and is funded by CRUK. His research is predominantly funded by various research councils, UK government agencies and charities (e.g. CRUK, SSA, NPRI, NIHR and UK Department of Health). He has previously received unrestricted research funding relating to smoking cessation from the pharmaceutical company Pfizer, which manufactures smoking cessation medicines. He has never received personal fees or research funding from alcohol, e‐cigarette or tobacco companies.
Keywords
- Addictive disorders
- COVID-19
- public health
- public health policy
- research
- treatment
